The American Journal of Managed Care

‘Our Responsibility Should Be to Give You the Closest Thing to a Normal Life’

The data presented covered everything from its mainstay acalabrutinib, sold as Calquence, to the eye-catching AZD0120, an ...
Oncology Nurse Advisor

Pirtobrutinib Approved for R/R CLL/SLL After Covalent BTK Therapy

Pirtobrutinib (Jaypirca®), a first-in-class noncovalent Bruton tyrosine kinase (BTK) inhibitor, has been approved by the FDA ...
The American Journal of Managed Care

Time-Limited Regimens Gain Notice, Offering a Break for Patients With Blood Cancer and Savings for Payers

The CLL17 trial showed noninferiority of fixed-duration regimens compared to continuous BTK inhibitor therapy, highlighting ...
Healio

VIDEO: ‘Overall excellent’ outcomes with acalabrutinib prior to chemotherapy in DLBCL

Please provide your email address to receive an email when new articles are posted on . ORLANDO — In this video, Brian T. Hill, MD, PhD, discusses promising results from a study examining the impact ...
Health.com

Inflammation: Causes, Treatment, and Impacts on Your Health

Infections that do not go away or abnormal immune responses may cause chronic inflammation. Chronic inflammation can lead to diseases like asthma, heart disease, and rheumatoid arthritis. Avoiding ...